Neurocrine Biosciences (($NBIX)) has held its Q4 earnings call. Read on for the main highlights of the call. Neurocrine Biosciences’ earnings call ...

One way to get an idea of the market sentiment on a stock is to check its rate of institutional ownership. In the case of ...

New research using publicly-shared DNA barcodes and citizen science images have provided new evidence on the establishment and spread of a biological control agent used for the control of the major ...

Neurocrine Biosciences Q4 earnings topped forecasts, but revenue slightly missed. Analysts see Ingrezza's long-term growth ...

Neurocrine Biosciences exceeded earnings expectations for Q4 2024, driven by robust sales from key product Ingrezza, while revenue slightly missed estimates.

Neurocrine Biosciences, Inc.’s NBIX share price has dipped by 18.53%, which has investors questioning if this is right time ...

David W. Boyer, the Chief Corporate Affairs Officer at Neurocrine Biosciences Inc. (NASDAQ:NBIX), a biopharmaceutical company currently valued at $15.4 billion, recently sold shares of the company's ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $169.43, a high estimate of $190.00, and a low estimate of $148.00. Observing a ...

We recently compiled a list of the 12 Best Low Risk High Growth Stocks to Invest In. In this article, we are going to take a look at where Neurocrine Biosciences, Inc.